{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:49:20Z","timestamp":1761630560157},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.berh.2009.11.006","type":"journal-article","created":{"date-parts":[[2010,8,22]],"date-time":"2010-08-22T08:38:42Z","timestamp":1282466322000},"page":"553-563","source":"Crossref","is-referenced-by-count":26,"title":["Targeting the B Cell in Rheumatoid Arthritis"],"prefix":"10.1016","volume":"24","author":[{"given":"Stanley B.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2009.11.006_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained Improvement in Rheumatoid Arthritis following a Protocol to Designed to Deplete B Lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2009.11.006_bib2","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.4049\/jimmunol.180.7.4994","article-title":"Suppression of Proteoglycan-Induced Arthritis by Anti-CD20 B cell Depletion therapy is Mediated by Reduction in Autoantibodies and CD4 + Reactivity","volume":"180","author":"Hamel","year":"2008","journal-title":"J of Immunology"},{"key":"10.1016\/j.berh.2009.11.006_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/smim.1994.1008","article-title":"The Role of B cell Abnormalities in the Systemic Autoimmune Syndromes of lpr and gld Mice","volume":"6","author":"Eisenberg","year":"1994","journal-title":"Semin Immunol"},{"key":"10.1016\/j.berh.2009.11.006_bib4","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","article-title":"T cell activation in rheumatoid arthritis is B cell dependent","volume":"167","author":"Takemura","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.berh.2009.11.006_bib5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2567.1999.00772.x","article-title":"Do self-perpetuating B lymphocytes drive human autoimmune disease?","volume":"97","author":"Edwards","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.berh.2009.11.006_bib6","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/art.22020","article-title":"Therapeutic B Cell Depletion and Regeneration in Rheumatoid Arthritis","volume":"54","author":"Silverman","year":"2006","journal-title":"Arth and Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib7","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic Changes Following B Lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arth and Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1084\/jem.173.2.487","article-title":"of Antigen-antibody Complexes by rheumatoid Factor B cells","volume":"173","author":"Rosnek","year":"1991","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.berh.2009.11.006_bib9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1084\/jem.187.7.1009","article-title":"B Lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion","volume":"187","author":"Fu","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.berh.2009.11.006_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","article-title":"Molecular Cloning of the Human B cell CD20 Receptor Predicts a Hydrophobic Protein with Multiple Transmembrane Domains","volume":"7","author":"Einfield","year":"1988","journal-title":"EMBO J"},{"key":"10.1016\/j.berh.2009.11.006_bib11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Chynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2009.11.006_bib12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic Activity of humanized anti-CD20 Monoclonal Antibody and polymorphism in IgG Fc Receptor FcGamma R111a Gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.berh.2009.11.006_bib13","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIB Randomized Trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arth and Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab Pharmacokinetics in Patients with rheumatoid Arthritis: B cell Levels do not Correlate with Clinical Response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.berh.2009.11.006_bib15","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I\/II dose-escalation trial of Rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib16","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib17","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1002\/art.22967","article-title":"Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment","volume":"56","author":"Onno Teng","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood b cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leaandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab:mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2009.11.006_bib20","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/art.23473","article-title":"Anti-CD20 Therapy in patients with rheumatoid arthritis","volume":"58","author":"Roll","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib21","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2009.11.006_bib22","first-page":"1390","article-title":"Continued inhibition of structural damage in rheumatoid arthritis patients treated with rituximab at 2 years: REFLEX study","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib23","unstructured":"Tak P.P, Cohen S, Emery P et\u00a0al. Clinical Repsonse Following The First Treatment Course with Rituximab: Effect of Baseline Autoantibody Status. EULAR meeting 2008. FRI0192."},{"key":"10.1016\/j.berh.2009.11.006_bib24","unstructured":"Silverman G, Schwartzman S, Townsend M et\u00a0al. Identification of Biomarkers for enhanced Benefit to Rituximab in Rheumatoid Arthritis: Role of Autoantibodies and Inflammatory Markers. Abstract ACR meeting 2009"},{"key":"10.1016\/j.berh.2009.11.006_bib25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ard.2007.085787","article-title":"Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2009.11.006_bib26","unstructured":"Emery P, Rigby WF, Combe B, et\u00a0al. Efficacy and safety of rituximab as first-line biologic therapy in patients with active rheumatoid arthritis: results of a phase III randomized controlled study (SERENE). ACR Abstract 08-A-1290-ACR meeting 2008."},{"key":"10.1016\/j.berh.2009.11.006_bib27","unstructured":"Rubbert-Roth A, Tak PP, Bombardieri S, et\u00a0al. Efficacy and safety of various dosing regimens of rituximab in patients with active RA; results of a phase III randomized study (MIRROR). ACR Abstract 08-A-1024-ACR meeting 2008."},{"key":"10.1016\/j.berh.2009.11.006_bib28","unstructured":"Mease PJ, Cohen S, Gaylis NB, et\u00a0al. Efficacy, safety, and dose frequency of retreatment with rituximab in RA: results from a randomized controlled trial (SUNRISE). ACR Abstract 08-A-3705-ACR meeting 2008."},{"key":"10.1016\/j.berh.2009.11.006_bib29","unstructured":"Tak PP, Rigby W, Rubbert A et\u00a0al. Inhibition Of Joint Damage and Improved Clinical Outcomes With a Combination Of Rituximab And Methotrexate In Patients With Early Active Rheumatoid Arthritis Who Are Na\u00efve To Mtx: A Randomized Active Comparator Placebo Controlled Trial. EULAR meeting 2009:Abstract OP-0022"},{"key":"10.1016\/j.berh.2009.11.006_bib30","unstructured":"Bingham C, Looney R, Deodhar A, et\u00a0al. Results from a controlled clinical trial (SIERRA) to evaluate primary and recall responses to immunizations in RA patients treated with rituximab. ACR Abstract 08-A-3626-ACR Meeting 2008."},{"key":"10.1016\/j.berh.2009.11.006_bib31","unstructured":"Genovese M, Breedveld F, Emery P et\u00a0al. Rate of Serious Infections in Rituximab Treated Patients with Rheumatoid Arthritis Who subsequently Received Other Biologic Therapies. Abstract 0097 EULAR 2009."},{"key":"10.1016\/j.berh.2009.11.006_bib32","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib33","unstructured":"van Vollenhaven RF, Emery P, Bingham C.O. Long-Term Safety of Rituximab: Follow-up of the RA Clinical Trials and Re-Treatment Population. EULAR meeting 2009 meeting.OP-0026."},{"key":"10.1016\/j.berh.2009.11.006_bib34","author":"Genentech and Biogen"},{"key":"10.1016\/j.berh.2009.11.006_bib35","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive Multifocal Leukoencephalopathy after Rituximab Therapy in HIV-negative Patients: a Report of 57 Cases from the Research on Adverse Drug Events and Reports Project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.berh.2009.11.006_bib36","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I\/II randomized, blinded, placebo-controlled, dose-ranging study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib37","unstructured":"Burge D;Chopiak V,Dvoretskiy L, et\u00a0al. TRU-015 Improves Rheumatoid Arthritis Disease Activity in a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 2 Dose Ranging Trial. Abstract. ACR meeting 2007."},{"key":"10.1016\/j.berh.2009.11.006_bib38","unstructured":"Stromatt S, Chopiak V, Dvoretskiy L et\u00a0al. Sustained Safety and Efficacy of TRU-015 with Continued Retreatment of Rheumatoid Arthritis Subjects Following a Phase 2B Study. Abstract ACR meeting 2009."},{"key":"10.1016\/j.berh.2009.11.006_bib39","unstructured":"\u00d8stergaard M, Baslund B, Rigby W et\u00a0al. Ofatumumab (HUMAX-CD20), A Fully HumanCD20 MONOCLONAL Antibody, In the Treatment of Rheumatoid Arthritis. Early results from an Ongoing, Double Blind, Randomized, Placebo Controlled Clinical Trial. EULAR meeting 2007:OP0232"},{"key":"10.1016\/j.berh.2009.11.006_bib40","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1126\/science.1061964","article-title":"An essential role of BAFF in the normal development of b cells through a BCMA \u2013Independent Pathway","volume":"293","author":"Schiemann","year":"2002","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.berh.2009.11.006_bib41","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1073\/pnas.050580697","article-title":"Severe B cell Hyperplasia and Autoimmune disease in TALL-1 Transgenic Mice","author":"Khare","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.berh.2009.11.006_bib42","first-page":"200","article-title":"nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept","volume":"105","author":"Carbonatto","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.berh.2009.11.006_bib43","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","article-title":"Elevated Serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arth and Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib44","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B Cell Activating Factor of the TNF Fasmily(BAFF) after Rituximab Treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2009.11.006_bib45","first-page":"S710","article-title":"Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator, combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous population","author":"McKay","year":"2005","journal-title":"Arth and Rheum"},{"key":"10.1016\/j.berh.2009.11.006_bib46","first-page":"S738","article-title":"Differential Responsiveness to Belimumab in combination with Standard of Care therapy in RF+, TNF inhibitor and methotrexate partial responder subgroups with moderate-severe rheumatoid arthritis","author":"Genovese","year":"1989","journal-title":"Arth and Rheum"},{"issue":"10","key":"10.1016\/j.berh.2009.11.006_bib47","article-title":"Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active sle: efficacy and safety results from the phase 3 BLISS-52 Study","volume":"60","author":"Navarra","year":"2009","journal-title":"Arth and Rheumatism"},{"issue":"Issue 1","key":"10.1016\/j.berh.2009.11.006_bib48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.23178","article-title":"Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase 1b, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study","volume":"58","author":"Tak","year":"2008","journal-title":"Arth & Rheumatism"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694209001429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694209001429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:47:24Z","timestamp":1559454444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694209001429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S1521694209001429"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2009.11.006","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}